Key Highlights:

  • Four companies with strong reported fundamentals fell between 10.00% and 20.11% on Friday, October 23, 2026.
  • Comfort Systems USA posted third-quarter diluted EPS of $13.91 and a $17.81 billion backlog, yet fell 10.00% to $1,151.46.
  • Tango Therapeutics holds $1.0 billion in cash and reported a 92% response rate for its pancreatic cancer combination before dropping 15.11%.
  • Phathom Pharmaceuticals grew VOQUEZNA revenue 88% in the second quarter, though it lowered its 2026 revenue range in July.
  • MacroGenics has a market value of about $184.6 million against pro forma cash of $327 million (calculated).

Which Stocks Fell on October 23, 2026 Even With Strong Fundamentals?

Four companies that recently reported strong operating or clinical figures fell sharply on Friday, October 23, 2026, and none has announced a catalyst for the move. Comfort Systems USA (NYSE:FIX) lost 10.00% to $1,151.46 after quarterly diluted EPS of $13.91 and a backlog of $17.81 billion. Tango Therapeutics (NASDAQ:TNGX) slid 15.11% to $23.71 with $1.0 billion in cash and a reported 92% response rate for its pancreatic cancer combination. Phathom Pharmaceuticals (NASDAQ:PHAT) dropped 15.55% to $5.92 after VOQUEZNA revenue of $74.3 million, up 88%. MacroGenics (NASDAQ:MGNX) fell 20.11% to $2.90 with $327 million of pro forma cash.

The group splits into one industrial contractor and three oncology or specialty drug developers. What they share is a gap between the latest published figures and the price reaction, which the companies have not explained.

Each company is covered below on its own basis, followed by a comparison of the size of the moves and the financial cushion behind each name.

Comfort Systems USA: Why Did Shares Fall After a Quarter of Sharp Growth?

The mechanical, electrical and plumbing contractor released third-quarter results on October 22 and held its call on October 23. Revenue reached $3.77 billion against $2.45 billion a year earlier, operating income rose to $624.6 million, and net income was $489.0 million versus $291.6 million.

The release carried no numerical guidance and said only that the company is positioned to grow organically through year end and into 2027. Cash stood at $2.16 billion, and free cash flow was $805.6 million. The next scheduled item is fourth-quarter and full-year reporting, and the company has not announced a date.

Over nine months, revenue totaled $9.90 billion and diluted EPS was $36.94 against $19.52, while operating margin improved to 16.6% from 15.5% in the quarter. Backlog was $9.38 billion a year earlier, so the order book has grown about 89.9% over twelve months (calculated).

Tango Therapeutics: Did the ESMO Opening Day Weigh on a Well-Funded Biotech?

Shares fell on the day the ESMO Congress opened in Madrid, where Tango said it would present Phase 1/2 data for vopimetostat with RAS(ON) inhibitors. The company has not announced a catalyst, so the timing may simply reflect positioning ahead of the presentation.

Earlier disclosures showed a 92% objective response rate and a 90% six-month progression-free survival rate in MTAP-deleted, RAS-mutant pancreatic cancer. A June update counted 11 responders among 12 patients. Second-quarter net loss was $55.3 million, and the company plans to finalize a randomized front-line Phase 3 design in the second half of 2026.

At $23.71 the shares sit about 14.3% below the August 10 close of $27.67 (calculated), within a 52-week range reported in August of $6.25 to $34.39. Two patients on the higher vopimetostat dose had severe side effects, which the full ESMO dataset may address.

Phathom Pharmaceuticals: Can 88% Product Growth Coexist With a Lower Revenue Range?

VOQUEZNA, the company's gastrointestinal drug, generated $74.3 million of second-quarter net revenue versus $39.5 million a year earlier, on about 325,000 prescriptions. The net loss narrowed to $17.6 million from $75.8 million as operating expenses fell to $63.1 million.

On July 30 the company trimmed its 2026 revenue range to $310 million to $325 million from $320 million to $345 million. Cash of $182.5 million sits against $671.3 million of total liabilities and a stockholders' deficit of $344.3 million. Third-quarter results arrive on October 29, 2026, and no catalyst has been announced for the latest decline.

About 1.7 million cumulative prescriptions had been filled by July 17, and covered prescriptions made up roughly 64% of the second-quarter total. Quarterly interest expense was $15.1 million, and a law firm announced an investigation into securities claims in August.

MacroGenics: Is the Poster Day Drop Out of Step With the Cash Position?

The decline coincided with the scheduled ESMO poster for MGC026, an antibody drug conjugate in a Phase 1 study of advanced solid tumors. In July the company said the study met its first-stage response threshold in a head and neck cohort, with 74 patients enrolled and no interstitial lung disease or ocular toxicity reported as of July 8.

Cash was $173.3 million on June 30, and pro forma cash of $327 million includes a $119.6 million manufacturing sale and milestone payments. Management guides the runway through 2028. The company has not announced a catalyst for the fall.

Second-quarter revenue was $32.8 million versus $6.9 million, helped by a $24.5 million partner milestone, and net income was $19.5 million including $89.2 million from discontinued operations. The company has 63,645,711 shares outstanding, which sets the market value used in the comparison below.

Strong Numbers, Weak Shares Compared: How Do the Four Gaps Stack Up?

The size of each drop differs from the quality of its supporting figures. MacroGenics fell furthest at 20.11%, which is 10.11 percentage points more than the 10.00% decline at Comfort Systems USA (calculated). The four names fell an average of about 15.19% (calculated). Phathom Pharmaceuticals fell 5.55 points more than Comfort Systems USA (calculated). Ranked from largest to smallest decline, the order is MacroGenics, Phathom Pharmaceuticals, Tango Therapeutics and Comfort Systems USA (calculated), a spread of 10.11 points from top to bottom (calculated). The two ESMO-linked names, Tango Therapeutics and MacroGenics, averaged a fall of about 17.61% (calculated), against about 12.78% for the two names without a congress link (calculated).

Balance sheet cover varies widely. MacroGenics pro forma cash of $327 million is about 1.77 times its market value of roughly $184.6 million (calculated). Tango Therapeutics cash of $1.0 billion equals about 18.1 quarters of its $55.3 million second-quarter net loss (calculated), while Phathom Pharmaceuticals total liabilities are about 3.68 times its cash (calculated). Comfort Systems USA backlog of $17.81 billion is about 4.72 times its third-quarter revenue (calculated).

What to Watch Next: Which Dates Could Test the Selling Pressure?

The ESMO Congress runs through October 27, 2026, four days after the session (calculated), with the MacroGenics lorigerlimab poster set for October 26. Phathom Pharmaceuticals reports third-quarter results on October 29, 2026, six days out (calculated), and expects Phase 2 topline data in eosinophilic esophagitis in the fourth quarter. Comfort Systems USA, Tango Therapeutics and MacroGenics have not announced dates for their next earnings reports.

MacroGenics fell the most, dropping 20.11% to $2.90.

No. None of the four companies has announced a catalyst for the October 23, 2026 move.

Phathom Pharmaceuticals reported VOQUEZNA revenue up 88%, while Comfort Systems USA revenue rose about 53.7% (calculated).